Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Single cell therapy may help to ease disease severity in Parkinson’s

Homogenous cell therapy — treatments using only one cell type — may ease disease severity, lessen motor symptoms, and improve activities of daily living in people with Parkinson’s disease, according to a new systematic review. These effects were observed during patients’ off periods, times when the medication wears off…

OM1 launches dataset to expand Parkinson’s evidence in real world

OM1 has launched a Parkinson’s disease premium dataset to expand real-world evidence on the progression of Parkinson’s progression and its treatments. The goal is to have a comprehensive view of the course of patients’ disease and contribute to accelerating research, assessing therapies’ effectiveness, and supporting procedures to…

Serina-AgeX merger to develop treatment for advanced Parkinson’s

Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease. The company will continue under the Serina name and expects to submit an investigational new drug application (IND) for SER-252 to the U.S. Food…

Lixisenatide may slow disease progression, early data show

Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with Parkinson’s disease, indicate the treatment may slow the progression of motor symptoms. The LixiPark (NCT03439943) trial is evaluating lixisenatide’s effectiveness as add-on therapy in 156 people with early…

Oral therapy GT-02287 shows promise in Parkinson’s mice models

Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve cell degeneration, in mouse models of the disorder. Further, the treatment lessened recognizable features associated with Parkinson’s symptoms — such as alpha-synuclein…

Foundation invests $2.8M in 30 grants for innovative research

The Parkinson’s Foundation is investing $2.8 million in 30 research grants to help advance potential new therapies for Parkinson’s disease. The focus is to accelerate pioneering research into several aspects of the disease, conducted by early career researchers or those more established. The ultimate goal is to find…

Cannabinoid that might help in Parkinson’s entering Phase 2 trial

Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could benefit people with a range of neurological conditions, including Parkinson’s disease. The safety and efficacy trial, approved to take place in Israel, is expected to begin enrolling children with…